!     "   

            

#$ %&&'% (%)#)&

%*% &'+, '*%*' -%.',&' --%.% /00/ BACKGROUND 7 Hyaluronan 7 Composition, structure and distribution 7 Involvement of hyaluronan in cellular and pathological events 9 Proliferation 9 Migration 9 Development and embryogenesis 10 Inflammation and fibrosis 11 Hyaluronan biosynthesis and catabolism 12 Hyaluronan synthesising -Hyaluronan synthases (Has) 12 Hyaluronan biosynthesis 13 Hyaluronan degrading enzymes- 14 Turnover of hyaluronan in tissues 16 Regulation of hyaluronan biosynthesis 17 Growth factors 17 Regulation of synthesis 17 Regulation of degradation 18 Hyaluronan binding proteins and receptors 19 Hyaluronan in tumors 21 General 21 Hyaluronan synthases in tumors 21 Hyaluronidases in tumors 22 Colon 24 Anaplastic thyroid carcinoma (ATC) 24 METHODOLOGY 25 The PROb model in paper II 25 quantification 26 The KAT-4 model in paper III 26 PRESENT INVESTIGATION 27 Aims 27 Results 27 (PAPER I) 27 (PAPER II) 29 (PAPER III) 30 Conclusions 32 GENERAL DISCUSSION AND FUTURE PERSPECTIVES 33 SAMMANFATTNING PÅ SVENSKA 36 ACKNOWLEDGEMENTS 40 REFERENCES 42 ABBREVIATIONS

ATC anaplastic thyroid carcinoma EGF epidermal growth factor GAG glycosaminoglycan GlcA D-glucuronic acid GlcNAc N-acetyl D-glucosamine Has hyaluronan synthase Has hyaluronan synthase protein Hyal gene Hyal hyaluronidase protein PDGF platelet-derived growth factor PROb progressively growing clone b TIFP tumor interstitial fluid pressure TGF-E transforming growth factor E Hyaluronan

BACKGROUND

The extracellular matrix of cells is an entangled network composed of different components including sugars and proteins that act in a concerted manner to create possibilities for cells to function. In cellular events such as embryogenesis, maturation and regeneration of tissues as well as in many pathological conditions, the extracellular matrix changes. The sugar hyaluronan is one component of the extracellular matrix that contributes to changes of its composition. The aim of this thesis was to study the genetic regulation and distribution of hyaluronan and how this affects the properties of tumor tissues. A better understanding of hyaluronan regulation combined with knowledge of the other extracellular matrix components will clarify the biology of normal and pathological conditions.

Hyaluronan

Composition, structure and distribution

Almost 70 years ago Meyer and Palmer described a high molecular weight polysaccharide (1) and during the following 5 decades it was called . Later on the polysaccharide was named hyaluronan since it is not acting as an acid at neutral pH. Hyaluronan is a member of the sugar-family glycosaminoglycans (GAGs). The GAGs are by definition linear carbohydrate polymers of disaccharide units. The GAG members and their respective sugar- compositions are shown in Table 1.

Name Sugar composition Sulfated Approx. Mr Peptide core Hyaluronan GlcA / GlcNAc - 105-107 - Chondroitin Sulfates GlcA / GalNAc + 10-50 x 103 + Dermatan sulfate GlcA or IdoA / GalNAc + 10-50 x 103 + Keratan sulfate Gal / GlcNAc + 5-15 x 103 + Heparan sulfate GlcA or IdoA / GlcNAc + 10-50 x 103 + Heparin GlcA or IdoA / GlcNAc + 5-20 x 103 + Table 1. Sugar composition of glycosaminoglycans (2).

Hyaluronan is synthesized in the interior of the plasma membrane by addition of alternating N-acetylglucosamine and D-glucuronic acid groups combined with E(1-4) and E(1-3) linkages (Fig. 1). In contrast to the other GAGs, hyaluronan is completely nonsulfated and lacks a peptide core (2). Hyaluronan is a large

7 Hyaluronan

polymer with an average length of approximately 25 000 disaccharide units, corresponding to a polysaccharide of 10 µm in length if straightened out, with a relative molecular weight of § 4 x 106 (3). Figure 1. Sugar composition of hyaluronan.

Hyaluronan is a major part of the hydrated milieu around cells called pericellular matrix. In solution hyaluronan forms a hydrated sphere where water is mechanically immobilized. Hyaluronan molecule can, through hydrogen bonds parallel with the chain axis, be stabilized and thereby form a stiffened helical configuration (4,5). Water can be trapped within this stiffened conformation of hyaluronan (6). Hyaluronan bound by cell surface receptors distributes at the cell surface in a brush-like manner (Fig. 2). Proteoglycans, such as aggrecan, interacting horizontally with the hyaluronan-chains can attract water through their negative charges (7).

Figure 2. The pericellular matrix.

8 Involvement of hyaluronan in cellular and pathological events

Hyaluronan is found at varying concentrations in most vertebrate tissues. In humans, hyaluronan concentrations span from 0.1-10 mg/ml in soft connective tissues such as vitreous body, skin and joint fluid, to 10-100 ng/ml in the circulation (8).

Involvement of hyaluronan in cellular and pathological events

Proliferation

Hyaluronan was found to be required for fibroblast detachment and mitosis (9). This was an early indication of that hyaluronan plays a role during proliferation. Cell rounding during mitosis was accompanied by a marked increase in hyaluronan synthesis. These observations have been further studied and confirmed in the following studies.

Hyaluronan and versican are abundant in artherosclerotic lesions (10). In vitro, hyaluronan and versican- rich pericellular coats were visualized around migrating and mitotic smooth muscle cells. These coats formed rapidly and their formation coordinated with detachment and mitotic rounding. Recently, there has been some focus on intracellular hyaluronan localized within the cytoplasm. When 3T3 fibroblasts proliferate they possess increased levels of intracellular hyaluronan, during the prophase/early metaphase of mitosis (11). This intracellular hyaluronan was distinct from the extracellular hyaluronan since it was localized within the nucleoli and nuclear clefts. A potential mechanism involving an interaction between hyaluronan and tubulin has been suggested. Microtubules are critical for cells passing through the cell cycle since they are responsible for the separation of the duplicated chromatin and thus critical for cell mitosis (12). Perhaps increased hyaluronan concentrations are needed for the cell to detach and prepare for mitotic rounding.

Migration

A pericellular environment containing high concentrations of hyaluronan may favor the migratory capacity for some cells. For both fetal and adult fibroblasts migratory activity and hyaluronan synthesis correlate positively. (13). The physicochemical nature of hyaluronan deposits results in hydration and expansion of extracellular matrix. This facilitates cell migration for fibroblasts but inhibits neutrophil locomotion. In a report by Knudson (14), two opposite functions are

9 Involvement of hyaluronan in cellular and pathological events

suggested: newly synthesized hyaluronan provides a migration promoting environment whereas hyaluronan-rich environments may provide a viscous barrier for migration. These differences may depend on which variant of the hyaluronan receptor CD44 that is present. The CD44 isoforms differ in their abilities to bind and internalize hyaluronan (14).

Over-expression of hyaluronan synthase increased migration of mesothelioma cells and addition of hyaluronan to hyaluronan-negative cells induced locomotion in a concentration dependent manner (15). Hyaluronan can also act as a negative regulator of migration. Overexpression of hyaluronan synthase or addition of hyaluronan to the culture media inhibits migration of CHO (Chinese hamster ovarian) cells (16,17). Formation of a hyaluronan-rich pericellular matrix is associated with migratory smooth muscle cells exhibiting motile morphology (10). It is proposed that hyaluronan interferes with fibrin polymerization thus creating increased fiber size and porosity of fibrin clots (18). The migration of glioblastoma cells in hyaluronan containing fibrin gels was not inhibited by the addition of antibodies against CD44, but by the addition of antibodies against Dv and E1- integrins. The authors concluded that hyaluronan modulates fibrin polymerization and thus the effect of hyaluronan on cell migration may be an indirect effect.

Development and embryogenesis

Cell movement in embryonic tissues is facilitated by hydration and swelling of the extracellular matrix, thereby enabling cells to migrate (19). Migration of embryonic cells, coincides with increased hyaluronan amounts in the embryonic extracellular matrix. A hyaluronan rich extracellular matrix provides spaces suitable for cell migration, between cell-layers and collagen fibers within the stroma. However, when migration ceases, a concomitant decrease in the amount of hyaluronan was observed (19). During early gastrulation events in Xenopus laevis (African green frog) one of the major expressed genes was denoted DG42. This gene was later shown to encode hyaluronan synthesis (20)

The most striking evidence of hyaluronan´s importance in embryonic development is that the genetic disruption of hyaluronan synthase 2 (Has2)* leads to impaired cardiac morphogenesis (21). The underdeveloped heart valves of Has2 knockout mice resulted in embryonic lethality and closely resembled the knockout phenotype in versican deficient mice (a hyaluronan binding

*Gene names are written in italics (Has), protein names are written in non-italics (Has).

10 Involvement of hyaluronan in cellular and pathological events

proteoglycan). Impaired cardiac morphogenesis caused by a deficiency of Has2 could be recovered by exogenous addition of hyaluronan to heart tissue explants. Has1 and Has3- knockout mice do not exhibit any detectable defects and most likely can Has2 replace their respective functions (21).

Inflammation and fibrosis

Elevated levels of hyaluronan in serum are detected in several pathological conditions such as liver cirrhosis, rejection of transplanted livers, as well as in rheumatoid arthritis and lung fibrosis (22). This depends on increased hyaluronan production, and/or on impaired clearance of hyaluronan in tissues and blood. In experimental lung fibrosis, induction of lung damage results in increased hyaluronan content, most likely due to both increased synthesis (23) and decreased degradation. Limited degradation of hyaluronan in lung fibrosis is suggested to depend on impaired hyaluronan receptors on alveolar macrophages (24). When the hyaluronan content decreases some days after injury, an increase in collagen synthesis occurs eventually leading to a fibrotic lung (23,24).

Hyaluronan synthesis is regulated by numerous pro-inflammatory factors and cytokines both in vitro and in vivo (25). CD44 and hyaluronan interactions have been extensively studied in several inflammatory models. The expression of the cell adhesion molecule CD44, on leukocytes and parenchymal cells, is up regulated during inflammation. Anti-CD44 antibodies inhibit inflammation in experimental models of collagen-proteoglycan induced arthritis, cutaneous inflammation and inflammatory bowel disease. Treatment with anti-CD44 also decreases edema formation and leukocyte infiltration in murine arthritis (26). Activated T-cell rolling can be mediated through CD44, although primary adhesion is often considered to depend on selectins and their ligands (25). Based on the above findings it is likely that CD44 plays an important role in inflammatory processes.

Fetal skin heals without scar formation, which is distinct from post-natal, and adult wound healing in which scarring and fibrosis often occurs. Fetal wounds are not inflammatory and not infiltrated by polymorphonuclear leukocytes. Furthermore, fetal wounds exhibit rapid epithelialization and a hyaluronan rich extracellular matrix. In a wound-healing model in lamb, the fibrotic healing observed in adult tissues correlated with increased hyaluronidase activity and degradation of hyaluronan compared to fetal tissue (27). Increased hyaluronan

11 Hyaluronan biosynthesis and catabolism

levels may thus be important for the regeneration process observed in fetal wound healing.

Hyaluronan biosynthesis and catabolism

Hyaluronan synthesising enzymes-Hyaluronan synthases (Has)

In 1996 the first reports were published concerning the cloning of mammalian hyaluronan synthases (Has). Each one of the isolated cDNAs was capable to initiate hyaluronan production upon transfection into mammalian cells. The first , denoted mouse Has1, was highly expressed in brain and to a lesser extent in liver, skeletal muscle and pancreas (28). Later the same year another cDNA clone was identified as a hyaluronan synthase. It was isolated through screening of a human cDNA library in an attempt to find cDNA clones that encode proteins that introduced binding to a T-cell lymphoma cell line (29). This was the human homologue to mouse Has1 and they shared 96% amino acid homology, and were considered to originate from a single copy gene. High expression of Has1 mRNA was also detected in the ovary by Northern blot analysis.

Has2 was cloned the same year and showed high expression in the mouse embryo and in adult tissues such as brain, spleen and lung. Transcriptional analysis confirmed two bands in Northern blots, and this was suggested to reflect alternative splicing of poly(A) signals generating either 3.2 kb or 4.8 kb transcript sizes (30). The Has2 gene was also shown to be a single copy gene. Soon a third gene was detected, referred to as Has3 (31). The three Has genes encode E - glycosyltransferases with a highly conserved Asp also found in other genes with similar activities. The size of Has enzymes is predicted to be 65 kDa by computer analysis of the amino acid sequence and the approximated sizes have been confirmed by Western blot analysis (32).

The three mammalian Has genes are localized on different (33) and evolution of the Has-gene family supports the idea of a typical scenario of gene duplication events. Presumably three sequential gene duplication events have occurred, the first generating Has1 and Has2 lineage, followed by two events resulting in Has1 and an inactive Has1 pseudogene (found in Xenopus laevis, xHas-rs) and Has2 and Has3 (34), respectively. The Has1 pseudogene was probably lost in mammals since it has not been detected although several attempts have been made (35).

12 Hyaluronan biosynthesis and catabolism

Hyaluronan is found in all vertebrates so far investigated and mammals express all three Has isoforms. Even some strains of bacteria have the ability to produce hyaluronan. Bacterial hyaluronan is incorporated in the capsule surrounding bacteria. The feature to produce hyaluronan is most likely a consequence of a functional convergent evolution from other genes encoding proteins involved in encapsulation of bacteria (35). The genome of the human pathogen group A Streptococcus pyogenes contains a has operon which includes hasA, hasB and hasC genes. These genes are active in the production of a hyaluronan-containing capsule. This capsule is important for this pathogen to escape discovery by the immune system, and is therefore considered as a virulence factor. HasA is the gene encoding hyaluronan synthase, hasB encodes a UDP-dehydrogenase activity that enables the bacteria to convert UDP-glucose to UDP-glucuronic acid, whereas hasC possesses to UDP-glucose pyrophosphorylase (36). The genome of the virus Chlorella PBCV-1, which infects green algae, contains a gene encoding an enzyme with hyaluronan-synthesizing capacity. The gene is expressed early during the infection event, but its function is unknown. This provides the first known example of a virus that expresses a gene for carbohydrate production. (37).

Hyaluronan biosynthesis

The Has enzymes use precursors of uridine diphospho-sugars for the polymerization of hyaluronan. The enzymes are unusual in that they possess both E1-4GlcNAc and E1-3GlcA transferase activities and are able to translocate hyaluronan chains through the membrane (38,39). The Has enzymes are located in the plasma membrane (Fig. 3). They are predicted to span the membrane several times with the active site presumably located in the cytoplasm (40). It has been reported that the sugars are added to the reducing end of the chain, although no studies have yet been performed on pure enzyme preparations but rather on membrane preparations (41-43). A cluster of basic amino acids in the C-terminal part of the Has enzyme is predicted to interact with the growing polysaccharide as it protrudes the extracellular space (35). Potential sites for E1-3GlcA and E1- 4GlcNAc transferase activities are predicted to reside in the large intracellular part, as evidenced by site directed mutagenesis of Has1 (44).

13 Hyaluronan biosynthesis and catabolism

Figure 3. Suggested topology of Has enzyme.

The exact membrane topology, positions of active sites and how hyaluronan is transferred through the membrane have not yet been determined for any Has enzyme (40).

Hyaluronan synthesis is energy consuming, requiring two types of UDP-sugars, divalent ions and a neutral pH. The vertebrate Has proteins show higher affinity for UDP-GlcA than for UDP- GlcNAc and therefore the availability of UDP-GlcA have been proposed to be rate limiting. It therefore follows that the activity of the conversion enzyme UDP-glucose dehydrogenase, that forms UDP-GlcA, is of special importance for hyaluronan synthesis. In vitro studies revealed that Has can polymerize 10-100 sugars/sec and within 5-10 minutes a chain of 1-10 x 106 Da is produced (35). Has1, 2 and Has3 synthesize different sizes of hyaluronan polymers, indicating that the nature of the Has polypeptides regulates the polysaccharide length (16,31,45).

Hyaluronan degrading enzymes- Hyaluronidases

The turnover of hyaluronan in the extracellular matrix is rapid. Enzymes capable of hyaluronan degradation are known as hyaluronidases. The hyaluronidases act in concert with two exoglycosidases that remove sugars from the non-reducing end, a E-N-acetyl glucoseaminodase and a E-glucoronidase (46). The mammalian hyaluronidases are E-endo-N-acetyl-glucosaminodases, which degrade both hyaluronan and chondroitin sulfate, and to some extent, dermatan sulfate. The only hyaluronan specific hyaluronidases known to date are found in Streptococci,

14 Hyaluronan biosynthesis and catabolism

Pneumococcus and Streptomyces hyalurolyticus (46). Hyaluronidases were first described as spreading factors found in tissue extracts of testis. They facilitated diffusion of antiviral vaccines, toxins and dyes. Hyaluronidase activity can be detected in the venom of snakes, bees, scorpions and spiders (47). The most studied hyaluronidase, PH-20, is expressed in testis as two forms. During fertilization, one form of PH-20 is present on the surface of the acrosomal head of the sperm. This enables the sperm to penetrate the hyaluronan-rich extracellular matrix of the cumulus cells surrounding the egg. The other form of PH-20, located in the acrosomal vesicle, is required for the sperm to degrade surface-associated hyaluronan and to bind the surface of the egg (47).

Hyaluronidase 1 (Hyal1) is another mammalian hyaluronidase, originally isolated from serum (48). Hyal1 has an acidic pH-optimum and is expressed in several tissues (Table 2). Hyal1 is a 57 kDa protein, where post-translational makes up 8 kDa of the molecular weight. The concentration of Hyal1 in serum is low and it requires acidic pH to possess enzyme activity. In urine, Hyal1 exhibit a 100 times higher specific activity than in serum and is present as two forms, the 57 kDa protein and a 45 kDa proteolytic cleavage product of the 57 kDa protein.

The hyaluronidase Hyal2 is approximately 40% homologous to Hyal1. Hyal2 is a lysosomal hyaluronidase with a unique hyaluronan degrading capacity, resulting in hyaluronan fragments with a molecular mass of 20 000 (49). Hyal2 is expressed in liver, kidney heart and placenta (Table 2). In mice, it is expressed in brain during fetal development, and is silenced after birth (50). Therefore, Hyal2 has been proposed to play a role during the embryonic development of the brain (51). Hyal2 can also be expressed on the cell surface, linked to a GPI anchor, especially in transfected cells over-expressing the protein. When Hyal2 is expressed on cell surface it may act as a receptor for an oncogenic virus, namely Jaagsiekte sheep retrovirus (52). Hyal2 is predicted to be 50 times less active than Hyal1, and this might be the explanation why it only degrades hyaluronan to 20 kDa fragments. Experiments with very low concentrations of other hyaluronidases also resulted in this degradation product. Hyal1 and 2 are both found in environments having neutral pH, although their enzymatic activities have acidic pH optimums. A possible explanation is that enzyme-substratum binding occurs in neutral pH whereas the hydrolysis of hyaluronan starts after transfer to a more acidic microenvironment (52).

15 Hyaluronan biosynthesis and catabolism

There are six chromosomal paralogues to the hyaluronidase genes, clustered on chromosomes 3p21 and 7p31. The names and known enzyme properties are listed in Table 2 (46,53). Hyal3 co-localizes with PH-20 in testis, although it remains to be determined if the uncharacterized Hyal3 has any function during fertilization. Hyal4 is believed to be an enzyme degrading chondrointin sulfate rather than hyaluronan, despite its name (46). Considering the structural similarities between hyaluronan and chondroitin sulfate it might be reasonable to speculate that enzymes degrading these polysaccharides are obtained through common evolutionary events. HyalP1 is proposed to be an inactive pseudogene (46).

Chromosomal Gene Protein Degradation Expression in pH cluster product of non-pathological optimum hyaluronan conditions Hyal1 Hyal1 tetra/hexa- Serum, liver, kidney, 3-4 saccharides heart 3p21.3 Hyal2 Hyal2 20 kDa liver, kidney, heart, 4 placenta Hyal3 Hyal3 n.d Bone marrow, testis n.d Hyal4 Hyal4 - n.d n.d

7p31.3 SPAM1 PH20 tetra/hexa- Testis 4.5, 7.5 saccharides HyalP1 None - - - Table 2. The six hyaluronidase paralogues found in (46) n.d- not determined

Turnover of hyaluronan in tissues

Hyaluronan has a high turnover in the body. As much as one third of the hyaluronan in the body is degraded each day. A major part of the circulating hyaluronan is taken up by the liver and a minor part by the kidneys (2,4). In joints 20-30% of hyaluronan is catabolized by local degradation. The lymphatic tissue carries hyaluronan to the blood stream where 80-90% in degraded by receptor- mediated catabolism (2). Some of the receptors responsible for hyaluronan uptake and degradation are described in more detail below.

16 Regulation of hyaluronan biosynthesis

Regulation of hyaluronan biosynthesis

Growth factors

Several cell-growth regulating and inflammatory released polypeptides such as platelet derived growth factor BB (PDGF-BB), transforming growth factor 1 (TGFE1), epidermal growth factor (EGF), and interleukin 1D1E (IL-1D and -1E) have been reported to affect synthesis of hyaluronan in culture (54,55). PDGF is a dimer composed of either two A-chains or two B-chains or combination of one A- chain and one B-chain. Ligand binding to PDGF tyrosine kinase receptors initiates receptor dimerization. The PDGF receptors can form homo- or heterodimers of DDDE or EE, which upon ligand binding stimulate diverse cellular processes such as proliferation, differentiation, migration, extracellular matrix production and gene transcription (56). The TGF-E superfamily consists of more than 30 multifunctional proteins, including TGF-E1, -2 and -3 as well as inhibins, activins and bone morphogenetic proteins. TGF-E dimers exert their signaling through binding to cell surface receptors exhibiting seronine/threonine kinase activity. In most cell types TGF-Es are growth inhibiting and stimulate deposition of extracellular matrix proteins. TGF-Es inhibit cyclin-Cdk kinases by prevention of pRB phosphorylation, which results in cell cycle arrest in late G1 phase (57).

Regulation of synthesis

Hyaluronan production in skin fibroblasts can be up regulated by addition of PDGF-BB or TGF-E1 to the culture medium (58). This activation was dependent on de novo protein synthesis and to some extent on activation of existing hyaluronan synthases, presumably through activation of protein kinase C (58). EGF and TGF-E1 could stimulate hyaluronan production in mouse cumulus cells (59). The data suggest that this stimulation involved tyrosine kinase activity and an increased transcriptional activity (59).

Genetic cloning of the three Has isoenzymes (29-31) offered new tools for examining transcriptional Has . The TGF-E1 treatment of dermal fibroblasts and keratinocytes (60) stimulates Has1 and 2 genes independently. The effects on hyaluronan synthesis also differed between skin fibroblasts and keratinocytes, indicating altered functions for hyaluronan in epidermis and dermis (60). EGF increases both intracellular and pericellular levels of hyaluronan in keratinocytes (61).

17 Regulation of hyaluronan biosynthesis

PDGF-BB stimulates hyaluronan synthesis through induction of the Has2 gene in arterial smooth muscle cells (62). Stimulation with PDGF-BB also increases the synthesis of versican and link protein, proteins known to interact with hyaluronan in the pericellular matrix. The pericellular matrix of smooth muscle cells expanded by PDGF-BB treatment and the phenotype of arterial smooth muscle cells changed, indicating PDGF-BB as a potent regulator of extracellular matrix in these cells (62). In mesothelial cells Has2 is also up regulated by PDGF-BB treatment, whereas the expression of Has1 and 3 remains unaffected (32).

Has expression and regulation in chondrocytes, synovial and osteosarcoma cells responds differently to external factors. This indicates that expression of Has genes is cell-specific, as growth factors and cytokines affect hyaluronan synthesis distinctly in different cell types. Genetic expression of Has did not always correlate to changes in hyaluronan production. Furthermore, the Has mRNA levels are low although the expression is higher in vivo than in vitro (63). An interesting possibility is that Has1 is utilized for synthesis of secreted hyaluronan, whereas Has2 might be responsible for the production of pericellular hyaluronan (63). Interestingly, antisense inhibition of Has2 in articular chondrocytes inhibited proteoglycan retention and pericellular matrix assembly (64).

Disordered accumulation of hyaluronan is characteristic for the pathogenesis of thyroid-associated ophthalmopathy. The orbital fibroblasts predicted to be responsible for hyaluronan synthesis in vivo were observed to increase hyaluronan synthesis in vitro by addition of IL-1E (55). Orbital fibroblasts, unlike dermal fibroblasts, do not down-regulate hyaluronan production in vitro by addition of thyroid hormone, glucocorticoids, n-buturate or retonic acid. With respect to cell density, the orbital fibroblasts up-regulate hyaluronan production in confluent cultures, which is in contrast to findings with other mesenchymal cells (32,55).

Regulation of degradation

The rarely inherited disease IX, is due to a mutation in the Hyal1 gene (65). This lysosomal disorder results in hyaluronan accumulation in the lysosomes of macrophages, and to a lesser extent, in fibroblasts. The serum concentration of hyaluronan is 38 to 90-fold above normal in these patients. The widespread distribution of Hyal2 and the uncharacterized Hyal3 may to some extent compensate for loss of Hyal1 activity (65).

18 Hyaluronan binding proteins and receptors

In an attempt to characterize hyaluronidase inhibitors present in serum, Stern and coworkers reported evidence that the hyaluronidase inhibitors belonged to the inter-D-inhibitor family (66). Purified inter-D-inhibitor and an inter-D -inhibitor related protein, pre-D-inhibtor, could inhibit hyaluronidase activity. The serum inhibitor of hyaluronidase could reduce the activity of the neutral acting testicular hyaluronidase, but did not affect Streptomyces hyaluronidase. This indicates that the inhibition was hyaluronidase specific and not a consequence of protection of hyaluronan against degradation. In contrast, hyaluronidase of testicular type decreases the level of inter-D-inhibitor like protein (67). The presence of inter-D- inhibitor is required to stabilize the hyaluronan containing pericellular matrix, presumably through inactivation of hyaluronidase (66). Members of inter-D- inhibitor family are secreted during the acute phase response. The elevated hyaluronan concentrations in circulation during shock, septicemia and excessive burns may be a result of increased levels of hyaluronidase inhibitors (66).

Injury induced by irradiation causes increased levels of hyaluronan deposition in the lungs (23). The hyaluronan accumulation ceases later during the pathological process and is subsequently followed by collagen synthesis and lung fibrosis. The increase in hyaluronan was predicted to be a consequence of cytokine stimulated up-regulation of Has2. Hyal2 might be responsible for hyaluronan degradation since the Hyal2 gene expression is up-regulated shortly after, or simultaneously with, Has2 up-regulation as evidenced by transcriptional analyses of lung tissues. Furthermore, Hyal2 and Has2 gene expression in lung fibroblasts is up-regulated in vitro by TGF-E1. Interestingly, hyaluronan oligosaccharides consisting of 6-18 saccharide units could stimulate collagen gene expression in lung fibroblasts (23) suggesting that hyaluronan fragments affect the pathogenesis of lung fibrosis.

Hyaluronan binding proteins and receptors

Hyaluronan receptors can be expressed at the cell surface, in a soluble form or be located in cytoplasmic compartments. The hyaluronan receptor CD44 belongs to the CD44 family of adhesion receptors expressed on several cell types. The molecular weight varies between 80 to 250 kDa due to alternative mRNA splicing and post-translational modifications. The CD44 gene consists of a stretch of variant exons, v2-v10, and is mainly expressed in epithelial cells, tumor cells and lymphocytes. A hematopoietic isoform, referred to as CD44H, is the most common isoform. The post-translational modifications of CD44 consist of N-and O-glycosylation, sulfation and attachment of glycosaminoglycans (25). The major

19 Hyaluronan binding proteins and receptors

ligand for CD44 is hyaluronan, but proteoglycan modifications, alternative splicing and glycosylation can modify the activity of hyaluronan binding, thus some forms of CD44 also binds fibronectin, collagen, chondroitin sulfate and osteopontin. During inflammatory response, CD44 is involved in leukocyte recruitment, interactions between leukocytes and parenchymal cells, as well as binding and endocytosis of hyaluronan. However, variant forms of CD44 are not involved in the homeostatic processes, and are therefore of potential interest in inflammatory studies. Inflammation and immune activation are correlated to increased plasma levels of a soluble form of CD44, presumably obtained through proteolytic cleavage of cell-surface CD44 (25). Another hyaluronan receptor, Lyve-1, is a CD44-homologue exclusively located to lymph vessel walls. Lyve-1 is considered to be hyaluronan specific since it has no affinity for any other glycosaminoglycans tested (68).

RHAMM (receptor for hyaluronan mediated migration) is a receptor that can be present at the cell surface, be secreted, or act as an intracellular hyaluronan receptor depending on alternative splicing. The intracellular variant of RHAMM is referred to as IHABP (intracellular hyaluronan binding protein). RHAMM is expressed by several cell types and, depending on which isoform is present, contributes to hyaluronan mediated migration, rearrangement of cytoskeleton and intracellular signal transduction (69,70). Recently the genes stabilin-1 and stabilin-2 were characterized and these genes encode the MS-1 antigen and hepatic hyaluronan clearance receptor, respectively. These functional hyaluronan receptors are present on the surface of endothelial cells and activated macrophages present in liver, placenta, spleen and the lymph node. The hepatic hyaluronan clearance receptor is predicted to be important for removal of hyaluronan from blood during steady-state tissue remodeling (71).

Layilin is a recently cloned and characterized hyaluronan receptor. Layilin exhibit a membrane-binding site for talin, a member of the ERM superfamily of linkers between actin cytoskeleton and the cell membrane. Therefore, the receptor is proposed to contribute to cell migration and morphology. Layilin shares no sequence homology to the other hyaluronan receptors (72). Link protein, aggrecan, versican, neurocan, brevican and TSG-6 are all examples of hyaluronan binding proteins. The aggregating chondroitin sulfate proteoglycan, termed aggrecan, exhibits a high affinity for hyaluronan, and interacts with hyaluronan to form the pericellular matrix described above (73).

20 Hyaluronan in tumors

Hyaluronan in tumors

General

As previously described hyaluronan is involved in proliferation, migration and wound healing. It is therefore not surprising that several tumors are associated with elevated hyaluronan levels since it may be crucial for the multistep progress of carcinogenesis. Increased hyaluronan concentrations are an unfavorable prognostic factor in breast, colorectal, mesothelioma, nephroblastoma (Wilm´s tumor) and a number of other solid tumors (74). However, other studies revealed that enrichment of tumor associated hyaluronan could serve as a favorable prognostic factor, as in of the lung. In this case dedifferentiated lung carcinomas lost most of hyaluronan staining compared to more differentiated carcinomas with a more promising prognosis (75).

Hyaluronan synthases in tumors

Transformation of normal cells is often combined with anchorage-independent growth. Transfection of Has2 can enhance the ability of tumor cells to grow detached from substratum (15,76), thereby enhancing their malignant properties. Introduction of Has2 in a fibrosarcoma cell line increased growth rate in a nude mice tumor model while cell density and angiogenesis were unaffected, suggesting that Has2 over-expression increased proliferation (76). Elevated serum levels of hyaluronan often characterize pleural mesothelioma, which is associated with asbestos exposure. The morphology of in vivo growing mesothelioma tumors appears as adenocarcinoma-like and fibrosarcoma-like, although theoretically it should only resemble sarcoma morphology due to its mesenchymal origin (77). The epitheilial-like morphology of mesotheliomas is not considered as “true epithelial” since abundant expression of syndecans-1 and -2 have been observed, which indicate mesenchymal origin. The fibroblast-like morphology is correlated with worse prognosis. Analysis of the proteoglycan profile may enable a better diagnosis (77) in addition to the morphological characteristics, which may help to understand and manage mesothelioma cases better. Has2 transfection of a mesothelioma cell line, negative in hyaluronan production, changed the morphology from epithelial-like to fibroblastic. It also increased expression of cell cycle regulatory proteins and increased the migration of Has2-transfectants (15). Hyaluronan and proteoglycan production can change the morphology of mesothlioma in vitro (15,77) but one should be careful with

21 Hyaluronan in tumors

extrapolations since their morphlogy is affected by serum substituents (77) and might be differentiated during several passages.

The ability of prostate cells to form metastases in bone marrow is most likely connected to properties influencing binding of cancer cells to bone marrow epithelial cells. Transfection of sense Has2 or Has3 cDNA induced binding of prostate cells to bone marrow endothelial cells, whereas antisense transfectected cells failed (78). As reported by Liu et al, Has3 transfection promoted cell growth both in vivo and in vitro (79). The cell growth of Has3 transfected cells was not inhibited by cell contacts, which is characteristic for untransfected prostate cancer cells, indicating that Has3 over-expression promoted multi layer growth (79).

Hyaluronidases in tumors

When considering tumor associated hyaluronan as an unfavorable prognostic factor (80,81), loss of hyaluronidase activity may be an event in the multi-step process of tumor development. The chromosomal location of Hyal1, 2 and 3 maps within a tumor suppressor loci referred to as LUCA-1, 2 and 3. Hemizygous deletion in this location on 3p21.3 occurs in many oral, head, neck and lung carcinomas (46,82). However, no mutations in the Hyal1 gene have been detected in any carcinomas. Interestingly, a proposed silencing mechanism of Hyal1 mRNA is reported in a number of cancer cell lines. Despite detection of transcriptional expression of Hyal1 the cells were observed to lack hyaluronidase activity and Hyal1 protein (46,83).

Treatment of tumors with the cytokine interferon-D (IFN-D) can induce tumor regression, but the efficacy of this treatment is highly variable (84). By using mice possessing different Hyal1 alleles, the opposite response to IFN-D treatment on tumor growth was achieved. In serum of Hyal1a mice, hyaluronidase proteins with 60, 120 and 140 kDa in size could be detected whereas serum from Hyal1b mice only contained a 60 kDa hyaluronidase protein. As a consequence, the group of mice having the Hyal1a allele exhibited three times higher hyaluronidase activity than mice having the Hyal1b allele. Melanoma and lung carcinoma was induced in a b Hyal1 and Hyal1 mice and treatment with IFN-D resulted in tumor growth reduction in Hyal1b mice whereas tumor growth was augmented in the Hyal1a mice (84). This indicates that increased hyaluronidase activity in circulation may reduce the possibility to decrease tumor growth by IFN-D treatment. Without any IFN-D treatment, the melanoma and lung carcinoma exhibited a reduced growth

22 Hyaluronan in tumors

pattern when injected in the mice bearing the high hyaluronidase activity Hyal1a allele compared to tumors obtained in Hyal1b mice, suggesting that higher hyaluronidase levels in circulation reduces tumor growth in this model (84).

In contrast to the above findings, where increased hyaluronidase activity in serum decreases tumorigenicity, increased expression of hyaluronidase in bladder, breast and prostate is reported to correlate with disease progression (85). In cell cultures of Hyal1 transfected squamus cell carcinoma, increased cell cycling was observed, suggesting that these cells preferentially entered S phase upon introduction of the Hyal1 gene (85). Over-expression of Hyal2 in astrocytoma cells accelerated tumor formation when injected intracerebrally and these tumors were more vascularized and had a larger necrotic area than tumors obtained from non-transfected astrocytoma cells (86). Necrosis can increase angiogenesis through activation of vascular endothelial growth factor (87). However, low molecular weight fragments of hyaluronan can also induce angiogenesis (88). Hyaluronan fragments are most likely a result of hyaluronidase action since none of the hyaluronan synthases have been reported to produce hyaluronan smaller than 105 Da in size (31). In a chick chlorioallantoic membrane assay, where one can analyze angiogenic response in the membrane underneath the eggshell, hyaluronan fragments of 4-25 disaccharides in length could increase angiogenesis (88). High molecular weight hyaluronan and oligosaccharides of chondroitin sulfate were unable to induce angiogenesis in this assay. Hyaluronidase overexpression of tumor cells has been observed to induce angiogenesis in vivo (89,90). In an attempt to elucidate the angiogenic impact of hyaluronidase treatment, endothelial cells were incubated with testicular hyaluronidase. This treatment could induce tubular formation of brain endothelial cells (91) and considered to be mediated through CD44. The brain endothelial cells used in this study produced low amounts of hyaluronan. The tubular formation might be addressed to the action of testicular hyaluronidase itself, rather than hyaluronan fragments (91). Whether it is the action of hyaluronidase itself or the hyaluronan fragments that can increase vascularization, is not known. Since the parameters are so tightly coupled it may be difficult to exclude one from the other, but there is also the probability that hyaluronan fragments and hyaluronidase act in concert to stimulate angiogenesis.

Tumor cells over-expressing Hyal1 (90) and Hyal2 (86) increase the necrotic area of tumors in vivo. Interestingly, hyaluronidase down-regulates the expression of an apoptosis inhibitory domain in FE65-like protein, thus making hyaluronidase a

23 Hyaluronan in tumors

candidate for induction of apoptosis (92). In vitro treatment of cancer cells with TGF-E1 can protect them from tumor necrosis factor (TNF)-induced cytotoxity. Testicular hyaluronidase counteracts this protective effect of TGF-E1 by inducing the Raf/MEK/MAP kinase pathway and renders cells susceptible to TNF-killing again (67). If hyaluronidase makes cancer cells vulnerable to TNF-killing it may imply that cell death and/or apoptosis increases. The in vitro observed opposing effects of TGF-E1 and hyaluronidase leads to the speculation that hyaluronidase might be a physiological inhibitor of TGF-E1 in vivo (67).

Colon carcinoma

The second/third most common type of cancer in the Western world is colorectal adenocarcinoma. The commonly used term colorectal cancer is somewhat misleading since there are biological and epidemiological differences between cancers in rectum and colon (93). The different types of cancers in colon are predicted to be associated with heredity, smoking, and diet (94). High consumption of animal fat and low fiber intake, especially in combination with smoking is correlated with disease occurrence. High levels of selenium in some geographical areas may explain the lower occurrence of colon cancer in these areas since the antioxidant glutathione peroxidase contains selenium and may play a protective role (93). Alterations in proto-oncogenes, such as ras, and several tumor-suppressing genes are reported to be a requirement for colon carcinogenesis. p53, a tumor suppressor gene, is mutated in a number of cancers including late stage of colon carcinomas. The DCC (deleted in colon cancer) gene, MCC (mutated in colon cancer) and APC (mutated in familiar adenomatous polyposis) genes are examples of common genetic alterations associated with colon carcinomas (93).

Hyaluronan is fairly abundant in normal colonic tissues and functions as a regulator of osmosis (95). In colorectal carcinomas, intense hyaluronan staining and a high percentage of hyaluronan positive cells correlates with poor outcome and hyaluronan staining intensity could predict survival (80). Metastatic potential of colon carcinoma is also predicted to correlate with CD44 expression, in particular CD44v6 isoform (96) and transformation of normal mucosa to colon carcinoma is associated with alterations in alternative splicing of CD44. (97). Adenocarcinoma cells secret factors that stimulate the hyaluronan synthesis in stromal intestine cells (98). Anaplastic thyroid carcinoma (ATC)

24 Methodology

Thyroid carcinomas are relatively uncommon cancers accounting to 1% of all cancers. Although the incidence is low this number corresponds to 90% of all endocrine cancers. The major cell types in the thyroid glands are follicular and parafollicular cells, where the follicular cells produce thyroid hormone and are the origin of both differentiated and anaplastic thyroid cancers (99). Differentiated thyroid carcinomas are associated with better prognosis than anaplastic thyroid carcinomas (ATC). Anaplastic thyroid cancer cells have lost much of gene expression characteristic for thyroid epithelial cells. Some differentiated thyroid carcinomas exhibit a more aggressive growth pattern and developed metastases and this phenomenon was correlated with hyaluronan staining (81). On the other hand, ATC is often highly aggressive with extensive metastases and commonly exhibits fibrotic characteristics with high collagen accumulation, mainly produced by stromal fibroblasts (100). Stromal compartments of experimental thyroid carcinoma consist of collagen and to some extent of hyaluronan (paper III) although the impact of hyaluronan in this model is unclear.

METHODOLOGY

The PROb model in paper II

A subclone of the cell line DHD-K12, isolated from rat colon carcinoma, was characterized as progressively growing clone b (PROb) (101). The obtained tumors after injection of PROb cells into BD-IX rats have been pathologically characterized as differentiated colon adenocarcinoma. The PROb rat colon carcinoma model is a syngeneic model. PROb tumors are rich in stromal hyaluronan although in vitro the PROb carcinoma cells do not exhibit any hyaluronan synthesizing or degrading capacity. To determine if increased hyaluronan production and degradation could affect growth rate we introduced, by stable transfection, cDNA for Has2, Hyal1 and empty vector to PROb cells before injection in rats. To study tumor growth in paper II the progressively growing clone b (PROb) was introduced to BDIX rats, with injection of 5 x106 cells in the right flank. The end point was set to a tumor size of approximately 1cm in diameter, determined through palpation. The animals were anaesthesized, tumors were excised and tumor growth was determined by dividing the wet weight of obtained tumors with number of weeks of growth. Hyaluronan content was determined by homogenization of tumor tissues with pronase and collagenase, followed by hyaluronan analysis using an hyaluronan specific assay (90). The

25 Methodology

hyaluronan distribution was visualized by staining of frozen tissue sections with a biotinylated hyaluronan specific probe, the G1 domain of aggrecan.

Angiogenesis quantification

To quantify angiogenesis in paper II (Table 2, paper II) we used an eyepiece grid inserted to the microscope. The grid contains 10 x 10 squares and by stepwise moving 1 mm throughout tissue specimen and collecting the parameters Q, P, V (Fig. 4) and I we could calculate angiogenic parameters and necrotic area by equations listed in Table 2, paper II, taken from Gundersen et al (102). Frozen tissue sections were stained with an endothelial specific marker, CD31. Viable area is defined as the part of tumor tissue that contains viable cells (Fig. 6, paper II), determined by hematoxylin stainins.

Figure 4. Angiogenesis methodology.

The KAT-4 model in paper III

The human anaplastic thyroid carcinoma cell line KAT-4 was injected to nude mice. As described in paper III, an inhibitor for TGF-E1 and -3 was used to study the effect of hyaluronan and collagen deposition. The aim of using a TGF-E inhibitor was to study the stromal effect of TGF-E, which is possible in the KAT-4 model since these cells do not themselves respond to TGF-E1 or TGF-E inhibitor treatment in cell culture. A soluble TGF-E receptor type II, which specifically inhibits TGF-E1 and -E3 action, was administrated through tail vein injections at a concentration of 10 mg/kg animal weight or, as a control, IgG2A.

26 Present investigation

PRESENT INVESTIGATION

Aims • To explore if Has genes are differentially expressed and regulated.

• To investigate how changes in hyaluronan synthesis and degradation effect the growth characteristics of experimental rat colonic carcinoma.

• To investigate the role for TGF-E in regulating stromal collagen and hyaluronan deposition in experimental anaplastic thyroid carcinoma.

Results

Differential expression and regulation of Has isoforms (Paper I)

The pattern of Has1, -2 and -3 mRNA expression was examined in five mesenchymal cell types to explore the relation of these three hyaluronan synthases to hyaluronan synthesizing capacity. The transcriptional Has expression and the hyaluronan production were compared in mesothelial-, mesothelioma-, and glioma cells, as well as in skin-, and lung fibroblasts.

Mesothelioma, a cancer of the pleural lining, which arises after asbestos exposure, is often correlated to increased hyaluronan concentration in the circulation (22). The mesothelioma cell line we examined showed a faint expression of Has3, whereas their normal counterpart, mesothelial cells, expressed all three isoforms (Fig. 1). Mesothelial cells produced high amounts of hyaluronan whereas mesothelioma cells only produced minute amounts. The contradictory finding of low hyaluronan production in cultures of mesotheliomas and the increased serum levels detected in patients may depend on cancer cell morphology (15,77) and/or the ability to secret hyaluronan stimulating factors (103). Mesothelioma cells overexpressing Has2 change phenotype from epithelial-like to fibroblastic morphology (15).

We also observed that cell density regulated hyaluronan production since the level of transcriptional expression was higher in subconfluent than in confluent cultures (Fig. 1). Denser cell cultures produced less hyaluronan per cell than sparsely

27 Present investigation

growing cell cultures (Fig. 2). This confirms an earlier study on dermal fibroblasts where suppression in hyaluronan production was observed in denser cultures (13).

Human lung fibroblasts and glioma cell lines express Has2 and Has3 genes and produced moderate to high amounts of hyaluronan. Skin fibroblasts exhibited only a faint Has3 expression and released low amounts of hyaluronan to the culture medium (Fig. 1 and 2).

Since mesothelial cells express all three Has isoforms, these cells were selected for our studies on growth factor regulation of Has gene expression. Stimulation with PDGF-BB induced an up-regulation of Has2 mRNA with a maximal stimulation reached after 6 h, whereas Has1 and Has3 genes were only slightly induced (Fig. 3). In contrast, addition of TGF-E1 or hydrocortisone reduced Has2 mRNA but did not affect the expression of mRNAs for Has1 and Has3 (Fig.4 and 8). The transcriptional effects correlated well to protein levels of Has1 and 2 as shown in Figure 7. Interestingly, the chain length of produced hyaluronan after addition of TGF-E1, fetal calf serum and PDGF-BB was of high molecular weight, above 2 x106 kDa, and relatively homogenous. Phorbol myristate acetate (PMA) treatment resulted in a polydisparse chain length (Fig. 6). Table 3 summarizes the findings in Paper I.

Celltype Has1 Has2 Has3 HA production Mesothelial +++ +++ ++ 16 Mesothelioma - - ++ 0.02 Lung fibroblast -+++6 Skin fibroblast --++2 Glioma - +++ + 12.5 Addition PDGF-BB TGF-E1 PMA Hydrocortisone

Table 3. Summary of Paper I. Relative gene expressions of Has1, 2 and 3 and hyaluronan production in subconfluent cell cultures. Hyaluronan (HA) secreted to culture medium presented as ng/ 1,000 cells. The symbol (-) indicate no expression. Lower panel show cell culture additions to mesothelial cell cultures and the respective changes in Has gene expressions and hyaluronan production as compared to control.

28 Present investigation

These analyses of Has gene regulation in mesothelial cells provided further evidence that Has genes are independently regulated. PDGF-BB preferentially stimulated the Has2 gene under these conditions and resulted in increased Has2 protein and accumulation of high molecular weight hyaluronan. Hydrocortisone decreased the expression of Has2 thus resulting in less hyaluronan secreted in to the culture medium. Has expression and hyaluronan production correlated well in the five mesenchymal cell types investigated. This indicates that transcriptional regulation of Has genes correlates with hyaluronan production.

Changes in hyaluronan biosynthesis affects the growth rate of colon carcinoma cell tumors (Paper II)

An elevated amount of hyaluronan in human colon carcinoma has been reported to correlate with an unfavorable prognosis (80). To investigate the importance of hyaluronan in colon carcinoma tumor progression, we transfected the rat colon carcinoma cell line, PROb, with either a cDNA coding for Has2 or a cDNA coding for Hyal1. As a control we transfected cells with empty vector, referred to as mock. In vitro characteristics of one clone each of PROb transfectants are listed in Table 4.

Has2 Hyal1 HA Hyadase HA Proliferation production activity binding Mock - - - - +++ +

Has2-d +++ - +++ - + +++

Hyal1-f - +++ - +++ n.d. +

Table 4. Summary of in vitro studies in Paper II. Relative values of in vitro characteristics of transfected PROb cells (clones Has2-d, Hyal1-f and mock). From the left: relative Has2 and Hyal1 gene expression, hyaluronan (HA) production, hyaluronidase (Hyadase) activity and binding of 3H-hyaluronan. The column to the right indicates relative proliferation.

The Has2 transfected PROb cells exhibited the highest growth rate in vitro. Furthermore, addition of exogenous hyaluronan to mock cells increased their proliferation rate to a similar degree as Has2 transfected PROb cells. Hyaluronan overproduction by Has2 transfected cells that led to a higher growth rate in vitro also exhibited a faster development of transplantable tumors in syngeneic rats, compared to the mock-transfectants. In contrast, Hyal1 overexpression suppressed

29 Present investigation

the growth rate of tumor cells both in vitro and in vivo (fig. 2 and 4). A significant positive linear correlation between growth rate and hyaluronan amount in the tumor tissues was found (Fig. 5b).

Tumors exhibiting high growth rate, derived from Has2 transfected cells, were less vascularized, but had a significantly larger viable tumor fraction compared to tumors generated from mock-transfectants. Interestingly, tumors derived from Hyal1-transfected cells had a significantly larger non-viable area than tumors derived from mock- and Has2-transfectants (Table 2, paper II). With regard to tumor vascularization, where Has2 tumors had significantly decreased vessel formation while it was increased in Hyal1 tumors, no studies examining the functionality of the vessels were performed. In vivo characteristics of one clone each of PROb transfectants are listed in Table 5.

Growth rate HA content Viable area Relative (gram/week) (µg/g dry tissue) vascularization Mock 0.3 520 62 ++

Has2-d 0.42 790* 79* +

Hyal1-f 0.15* 495 46* +++

Table 5. Summary of animal experiments in Paper II. Averages of growth rate, hyaluronan (HA) content and viable area in PROb tumor tissues (clones Has2-d, Hyal1-f and mock). For S.D. values and number of animals, please see Paper II. Significant change (p<0.05) from control, mock, is indicated with (*).

Our study demonstrates that Has2 overexpression promotes PROb carcinoma cell proliferation and tumorigenicity, whereas Hyal1 overexpression suppresses tumorigenicity in this experimental model for colon carcinoma. These findings suggest that hyaluronan in the pericellular matrix may affect tumor cell growth in a progressive manner.

A soluble TGF-E1 and -E3 inhibitor lowers collagen deposition in experimental anaplastic thyroid carcinoma (Paper III)

The stromal compartment of solid tumors displays varying degrees of fibrosis. Our intention was to study the fibrotic reaction in an experimental anaplastic thyroid carcinoma (ATC). The experimental ATC served as a model for ongoing fibrosis in tumor tissue, with focus on the deposition of two major stromal

30 Present investigation

constituents, collagen and hyaluronan. TGF-Es are potent stimulators of extracellular matrix components including hyaluronan and collagen (58,100). TGF-Es also possessess growth inhibiting effects on connective tissue cells (57). Administration of a TGF-E inhibitor, a soluble TGF-E receptor type II that specifically inhibits TGF-E1and -E3, was used to examine whether it was possible to affect stromal hyaluronan and collagen deposition. Based on two observations, namely that TGF-E1 or the TGF-E inhibitor did not affect proliferation of cultured KAT-4 cells; and that Smad2 phosphorylation was not affected by TGF-E1 stimulation of the cells, it was concluded that KAT-4 cells are refractory to TGF-E stimulation (105). Addition of exogenous hyaluronan did not affect the cellular growth of KAT-4 in a proliferation assay (Fig.1b). The properties of KAT-4 cells, as being inert to additions of TGF-E, TGF-E inhibitor and hyaluronan, thus make it a potential model for analyzing the influence of stromal hyaluronan in ATC.

Increased tumoral interstitial fluid pressure (TIFP) is suggested to form a barrier for penetration of anti-cancer agents into the tumor tissue (104). Previous studies on KAT-4 and TGF-E inhibitor treatment revealed that TGF-E inhibitor reduced the TIFP and increased the initial tumor growth (105). The effect of tumor size and TIFP was thought to involve changes in hyaluronan deposition since TGF-E is suggested to stimulate Has gene expression and hyaluronan production (59, 60). Conditioned medium from KAT-4 cultures stimulated hyaluronan production by dermal fibroblasts and this effect was abolished by the addition of the TGF-E inhibitor (Fig. 2a). Thus KAT-4 secrets TGF-E1 and/or TGF-E3, which are able to stimulate hyaluronan synthesis. KAT-4 cells also stimulated hyaluronan synthesis in skin fibroblasts through cell-cell contact, since co-culture of the two cell types resulted in a marked increase in hyaluronan production (Fig. 2b). The hyaluronan produced originated from dermal fibroblasts since KAT-4 produce undetectable amounts of hyaluronan (Fig. 1a). Addition of the TGF-E inhibitor to the co- cultures of KAT-4 and skin fibroblasts only slightly reduced the stimulating effect of KAT-4 (Fig. 2b), indicating that factors other than TGF-E are involved in cell- cell contact stimulation of hyaluronan production in skin fibroblasts. It is also possible that the TGF-E inhibitor was unable to penetrate cell-cell contacts thus limiting its effect.

The ATC cell line KAT-4 was injected in nude mice and the tumor-bearing mice were divided into two groups. The first group received, via tail vein injection, the TGF-E inhibitor and the second group (control) were injected with IgG2A. No obvious changes were detected between the groups, in histochemical analyses of

31 Conclusions

collagen deposition in tumor tissues and in situ hybridization with pro-D1(I) collagen mRNA. However, a decrease in collagen levels was observed in TGF-E inhibitor treated animals when analyzing hydroxyproline content of KAT-4 tumor tissues. A decrease of the transcriptional expression of pro-D1(I) collagen (Fig .5) supported the lower amount of hydroxyproline content observed in the group treated with the TGF-E inhibitor. The hyaluronan levels were only marginally increased in tumors treated with the inhibitor and no obvious differences in hyaluronan staining were observed between the groups (Fig. 3b). In contrast to the observed increase in hyaluronan deposition, a decrease in Has2 and Has3 mRNAs was observed (Fig. 5).

Our results show that inhibition of TGF-E1 and -E3 results in a reduced deposition of interstitial collagens whereas hyaluronan content was unchanged. The changes in TIFP and tumor size observed after TGF-E inhibitor treatment (105) were considered independent of hyaluronan deposition. Our results are compatible with that the formation of a tumor stroma with high collagen deposition may be part of the pathogenic mechanism for the generation of a fibrotic reaction in solid tumors.

Conclusions

- Has genes are differentially expressed in different cell types. The gene expression and hyaluronan synthesis is depending on cell density where denser cultures down-regulate hyaluronan synthesis.

- PDGF-BB, TGF-E1, PMA and hydrocortisone affect Has genes independently, where the Has2 gene is most markedly affected. The Has2 gene is up regulated in response to PDGF-BB but down-regulated in response to hydrocortisone.

- Has gene expression is well correlated to Has protein and hyaluronan synthesis in this system.

- Introduction of Has2 enhances tumor growth rate, whereas introduction of Hyal1 decreases tumor growth rate both in vitro and in vivo in a rat colon carcinoma model.

- Hyaluronan amounts in tumor tissues exhibit a positive correlation to growth rate in PROb derived tumors.

32 General discussion and future perspectives

- The necrotic fraction increases in Hyal1- derived tumors and decreases in Has2-derived tumors.

- Inhibition of TGF-E action in experimental anaplastic thyroid carcinoma significantly decreases stromal collagen whereas no obvious changes in hyaluronan levels or distribution were detected.

- Tumor-associated hyaluronan in PROb derived tumors correlated with increased growth properties, whereas stromal hyaluronan did not correlate to growth characteristics in the KAT-4 model.

GENERAL DISCUSSION AND FUTURE PERSPECTIVES

Hyaluronan, an abundant polysaccharide in the extracellular matrix, is involved in cellular functions such as proliferation, migration and differentiation. Hyaluronan is synthesized by three different hyaluronan synthase genes that are differentially expressed, regulated and give rise to Has proteins that exhibit different enzymatic activities (16,31).

Cell density is a key regulator of hyaluronan synthesis since denser cell cultures synthesize less hyaluronan per cell (32,55). In embryonic development hyaluronan is abundant when cells are motile but decreases when migration is suppressed. Hyaluronan is needed to form a hydrated milieu suitable for cell migration (19).

The Has2 gene is the most abundant isoform and is more susceptible for changes in cell culture conditions (32). The importance for Has2 is further demonstrated by lethality of Has2 knockout mice, whereas Has1 and Has3 are viable (21). Changes in Has expression can influence growth behavior of tumor tissues, where over-expression of Has mainly increases growth and metastatic potential of experimental tumors (15,76) and increases anchorage-independent growth (76). Excess hyaluronan levels in tumoral tissues may either depend on extended hyaluronan synthesis or loss of hyaluronidase activity. Loss of hyaluronidase may lead to overproduction of hyaluronan that stimulates growth, movement and metastatic behavior.

Introduction of Hyal genes in tumor cells results in larger necrotic fractions of experimental tumors (86,90) and delayed tumor development in some models

33 General discussion and future perspectives

(84,90). However, the hyaluronan content in Hyal1-derived PROb tumors was unchanged (90) compared with the control, indicating that overall hyaluronan content is not the only factor affecting the growth rate and necrosis in the PROb model. The finding that higher hyaluronan degrading capacity increased the necrotic area of PROb tumors tempted us to speculate that hyaluronidase can induce apoptosis. Hyaluronidase has been reported as a candidate for inducing apoptosis since it can down regulate the apoptosis inhibiting domain in the FE65 protein (92) and make tumor cells susceptible to TNF-killing (67).

Hyaluronan of high molecular weight can inhibit angiogenesis, whereas short hyaluronan fragments can induce angiogenesis (106). This is of interest considering our observations in the PROb tumor model that over expression of Has2 resulted in less vascularized tumors and the Hyal1 transfected tumors were more vascularized (90). Hyaluronan may be an important factor for promoting tumor growth and development through affecting proliferation, migration, apoptosis and angiogenesis.

To explore the function of hyaluronan in the fibrotic tumor model KAT-4 we used a TGF-E inhibitor since TGF-E can regulate hyaluronan synthesis in vitro (58-60). In many studies TGF-E is detected in fibrotic tissues and abolition of TGF-E action in a liver fibrosis model resulted in less accumulation of hyaluronan and a less severe fibrotic pattern (107). In lung fibrosis, hyaluronan accumulation occurs prior to collagen synthesis and fibrotic healing after induction of lung damage (24). Liver and lung fibrosis models reflect the result of one time induced organ damage resulting in fibrotic healing. The difference with the KAT-4 fibrotic pattern is that it probably reflects continuos, ongoing fibrosis. It is also possible that the fibrotic process proceeded too far in the KAT-4 model to be able to affect the hyaluronan accumulation by addition of TGF-E inhibitor. Nevertheless, the collagen deposition was reduced in this model by administration of the TGF-E inhibitor, resulting in a less fibrotic tumor tissue (Table I, paper III). Interstitual fluid pressure can be reduced by injection of hyaluronidase in osteosarcoma xenografts (108), although this treatment did not affect the hyaluronan distribution. The effect of hyaluronidase injection on TIFP was surprisingly fast, thus it is unlikely that it was depending on hyaluronan degradation. Hyaluronidase could have barely reached the tumor tissue, penetrated it and degraded hyaluronan within a minute. There were no changes in blood pressure and thus the effect of hyaluronidase administration reducing the TIFP of osteosarcoma xenografts works through a still unknown mechanism (108). In an

34 General discussion and future perspectives

attempt to elucidate the effect of hyaluronan on tumor interstitial fluid pressure (TIFP) in the PROb model, hyaluronan analysis of tumors with extreme high and low pressures was performed. No correlation between hyaluronan content and TIFP was observed (data not shown). Over-expression of Has2 or Hyal1 did not change TIFP in the obtained tumors, although the number of animals was too low to draw any conclusions either way (data not shown). Interestingly, the TIFP can be reduced in vivo by the soluble TGF-E inhibitor in the KAT-4 model (105). However, hyaluronan analysis of KAT-4 tumor tissues with either high or low TIFP revealed no difference between TGF-E inhibitor treated group and control group (105). In conclusion, it is unlikely that hyaluronan amounts affect the TIFP in subcutaneosly grown tumors.

The role for hyaluronan in tumorigenesis probably reflects a complex scenario. Hyaluronan directly associated with tumor cells might have a different function than stromal-associated. So far there is limited knowledge about Has and Hyal regulation in vivo. A long term study, perhaps with a tumor model where one follows variations in Has, Hyal and hyaluronan receptors over time could expand the knowledge. This in combination with analyses of collagens and proteoglycans might resolve some of stromal compartments role in tumors.

As stated already in the beginning of this thesis; when we understand better the functions and regulation of hyaluronan, combine it with knowledge of the other extracellular matrix components we can draw better conclusions and perhaps better predictions of the biology for normal as well as pathological conditions.

35 Sammanfattning på svenska

SAMMANFATTNING PÅ SVENSKA

Introduktion

Celler är per definition den minsta delen av en organism med de egenskaper som kännetecknar liv, d.v.s. förmåga till näringsupptag och förökning. Celler omger sig av ett skyddande hölje som kallas extracellulär matris. Denna matris har stor betydelse eftersom den skyddar cellen mot stötar och förmedlar de flesta kontakter med omgivningen. Cellen behöver kontakter med omgivningen så att den ska kunna få instruktioner om vad den behöver göra, t.ex. om den bör förflytta sig, föröka sig eller förinta sig själv. För att upprätthålla normala funktioner i ett organ kan kontakten med omgivningen behöva förändras, och den extracellulära matrisen är ständingt i förändring. En del av förändringarna står mängden hyaluronan för, eftersom hyaluronan är en betydande beståndsdel av den extracellulära matrisen. Vid vissa sjukdomstillstånd kan en imbalans i mängden hyaluronan uppstå. För mycket hyaluronan i lungvävnad kan försvåra andningen, däremot kan en ökning av mängden hyaluronsyra vara positivt vid sårläkning. Det blir mindre ärrbildning om det är stor mängd hyaluronan i vävnaden . Det beror alltså på vilket sammanhang hyaluronanet befinner sig i. Syftet med denna avhandling är att studera regleringen av hyaluronanmängden samt att undersöka hur hyaluronan kan påverka tumörtillväxt.

Kort bakgrund

Cellens uppbyggnad

Cellen är uppbyggd av vissa gemensamma komponenter. I mitten finns cellkärnan som kan liknas vid hjärnan och här finns allt DNA (Figur 1). De delar av DNA som ger information (kodar) för proteinproduktion kallas gener. Alla celler innehåller samma gener i dubbel uppsättning, med en från modern och en från fadern. Ett undantag är könscellerna som bara har en genuppsättning. Eftersom celler är olika, trots att de har samma gener, skiljer celltyperna sig från varann genom att ha olika gener påslagna. Utanför cellkärnan finns cytoplasman och här finns cellens maskineri (Figur 1). Här sker den mesta av produktionen som generna har givit order om. När en gen är påslagen innebär det att den delen av DNAt kopieras. Denna kopia kallas RNA och är förhållandevis liten och kan transporteras ut ur cellkärnan till maskineriet där det bildas ett protein. Proteinets beståndsdelar bestäms av utseendet (koden) på RNAt. Proteiner är cellens

36 Sammanfattning på svenska

redskap. Det finns olika typer av proteiner som har olika funktioner att erbjuda som t.ex. transportering av syre eller avfallsprodukter, genomföra rörelse eller medverka i kroppens immunförsvar. Enzymer är speciella proteiner som är aktiva i en kemisk process i kroppen. Det finns enzymer som tillverkar ämnen och andra som bara påskyndar kemiska processer.

Figur 1. Förenklad bild av cellens uppbyggnad.

Utanför cellens membran, som kan liknas vid våran hud, finns den extracellulära matrisen (Figur 1). Den extracellulära matrisen runt celler är uppbyggd av flera olika proteiner och kolhydrater. Dessa är sammanlänkade och bildar tillsammans ett nätverk. En av dessa kolhydrater är hyaluronan och samverkar med proteiner i den extracellulära matrisen.

Hyaluronan

Hyaluronan en kolhydrat, vilket innebär att den är uppbyggd av flera sockerenheter (monosackarider) som länkats ihop till en sockerkedja (polysackarid). Polysackarider utgör den mesta biomassan på jorden och fungerar i de flesta fall som stödjematrial. I växter finns polysackariden cellulosa i cellväggarna och i skalen på skaldjur finns polysackariden chitin. Ryggradsdjurens motsvarighet är troligen hyaluronan. De olika sorterna polysackarider är uppbyggda av olika sorters monosackarider. Hyaluronan utgör en viktig beståndsdel av t.ex. ledvätska och hud. Skillnaden med hyaluronan är att utöver sin strukturella betydelse även kan fungera som en signalmolekyl på cellnivå. Mängden hyaluronan ökar i samband med celltillväxt (proliferation), förflyttning (migration) och under den embryonala utvecklingen.

37 Sammanfattning på svenska

Figur 2. Produktions och nedbrytningsenzym för hyaluronan.

Hyaluronan tillverkas av ett produktionsenzym som kallas ”hyaluronan synthase” och förkortas Has. I en fungerande vävnad sker en balans mellan produktion och nedbrytning av hyaluronan. Nedbrytning av hyaluronan sker mha ett klippenzym som heter”hyaluronidas”, eller Hyal (Figur 2).

Sammanfattning av de arbeten som ingår i avhandlingen

Papper I. Genetisk reglering av de tre varianterna av produktionsenzym

Det finns tre likartade varianter av produktionsenzymet Has och även tre gener som kodar för dem. Vår frågeställning inför Papper I var: Om det finns tre gener som tillverkar liknande produktionsenzymer, är de då olika reglerade och uttryckta?

Vi undersökte fem olika celltyper och fann att de tre varianterna hade olika mönster av genuttryck för de tre Has-enzymerna. Vi fann också att de var olika reglerade (på- och avslagna) vid olika tillsatser av signalmolekyler till cellodlingen.

Papper II. Tillsats av produktionsenzym och klippenzym påverkar tumörtillväxt

Inför nästa projekt var vi intresserade av att undersöka effekten av tillsats av produktionsenzym respektive klippenzym till tumör celler. Bakgrunden var att andra forskare rapporterat om ett positivt samband mellan tumörtillväxt och mängden hyaluronan. En tumör kan beskrivas som ohämmad celltillväxt. Vissa tumörceller verkar utnyttja hyaluronan för att lättare föröka och förflytta sig.

38 Sammanfattning på svenska

Därför modifierade vi egenskaperna i colon cancer celler. Vi delade upp cellerna i tre grupper. Den första lämnade vi oförändrad och fick delta som referens, kallad ”mock”. Den andra gruppen celler fick en gen som kodar för produktionsenzym insatt och den tredje gruppen fick en gen med klippenzym.

Figur 3. De tre varianterna av tumörceller.

När dessa tre cellgrupper blev inplanterade i råttor visade det sig att de växte olika snabbt. När man jämförde tillväxten med kontrollen växte tumörerna med produktionsgenen snabbast och den med klippgenen långsammast (Figur 3).

Papper III. Kan vi minska mängden hyaluronan i tumörer genom att hämma en signalmolekyl?

I det sista arbetet ville vi ta reda på om vi kunde minska mängden hyaluronan i tumörvävnad. Tidigare studier från andra forskare visade att en signalmolekyl som heter TGF-E kan öka mängden hyaluronan i cellodling. Om man hämmar denna molekyl minskas trycket i tumören och det blir lättare att administrera cellgifter. Nu ville vi undersöka om vi blockerade denna molekyl (TGF-E , skulle vi få en mindre mängd hyaluronan då? En annan frågeställning var om trycket i tumörer beror på mängden hyaluronan. Det visade sig att mängden hyaluronan inte var påverkad av hämmning av TGF-EDet verkade istället som att det var en annan molekyl, collagen, som minskade i mängd.

Slutsats

Vi visade att regleringen av hyaluronanproduktion sker med olika påverkan på de tre generna. Vid tillsats av produktionsgenen ökade tumörtillväxten men minskade vid tillsats av klippgenen. Vi kunde inte påverka mängden hyaluronan med tillsats av en hämmarmolekyl. Mer studier om hyaluronans funktioner och dess reglering kan, i kombination med andra molekyler, ge viktig kunskap om normala och patologiska tillstånd.

39 Acknowledgements

ACKNOWLEDGEMENTS

I wish to express my sincere gratitude to:

My supervisor Evi Heldin for always being interested in the science of hyaluronan, the progress of my projects and for being generous with time for questions and discussions. She also helped me to mature from a naive to a less naive person and perhaps scientist.

The extra support and guidance I received from Prof Kristofer Rubin, sharing me generously some of his knowledge about tumor biology, tissue staining and never- ending ideas for new experiments. Prof Nils-Erik Heldin, thank you for nice collaboration and for your hard work with the Northerns and with the last manuscript.

My examiner Prof Ulf Lindahl for giving me time whenever I asked for it and for giving me wise words along the way.

Thank you Evi, Kristofer, Johan, Mehdi, and Peter McCourt for improving this thesis.

My friends and colleagues in the lab; Dr. Dr. Jonas Brink (for “happy-Friday- humor”, Gotland, and discussions concerning hopeless antibodies and silly synthases) Masanobu Suzuki, Priit Teder and Tomas Asplund. Marianne Svarvare (for always being so nice), Mehdi Rahmanian (for Persian history-lesions and friendship), Johan Lassus, Yuejuan Li and Lingli Li.

All nice lab-neighbors like Maria Thuveson (for good help, lots of laughter and for being a good source for any kind of information), Annika Armulik (for being a good travelling- guide and a very good friend) Mårten Larsson (for innebandy- games, coca-cola-breaks and non-scientific discussions) Kajsa Lilja, Håkan Pertoft and Erik Fries group, past and present. Ulf Lindahl group: Johan Kreuger (discussions about everything except science, lots of fun), Dorothe, Maarten, Ahn- Tri, Elisabeth, Marion etc.etc. In D11:3: Ellen, Christian S, Alexei and Ann-Marie (all four for helping me with the last two papers and for information of experimental tumor biology and stainings). Gunilla, Åsa, Åke, Eva and the others that I might have forgotten to mention. Sorry.

40 Acknowledgements

Prof Torvard Laurent for being an excellent source of scientific inspiration. The excellent service minded Liisa Holmsäter, Erika Enström, Barbro Lowisin, Maud Pettersson, Olav Nordli, Tony Grundin, Piotr Wlad and Kerstin Lidholt. With the students I received good help from Inga-Lisa Karlsson Lööf and Örjan Zetterqvist.

Ulf Lindahl, Kristofer Rubin, Ludwig Institute, Lena Claesson-Welch, Bengt Gerdin and Fries groups thank you for letting me use some of your equipment.

The department, medical biochemistry and microbiology, thank you for providing good facilities and atmosphere to work in.

Viktoria Göransson, för att vi “försökte i alla fall” och vi hade det trevligt under tiden. (RMIC = Rackarns Mariga I Cellkultur)

Tack för alla knäppa mail från statstjänsteman Carlander.

Innebandy-gänget, tack för att jag blev accepterad som en av killarna.

Alla dessa luncher!! Hur kul har det inte varit att få en lunch-break med Er? Maria, Jonas, Mårten, Johan (typ 1000 st) och nu senast med Ann, Ann-Sofie och Per. Ann-Sofie och Per, tack för att ni är så trevliga, kom nu snällt tillbaka till Uppsala efter UK… Innan dess: Let’s go for the gös. Ann-Sofie, som du skrev var det skönt att dela avhandlingsdetaljerna med någon. Tack.

Tack till: Anna W, Karin L, Katarina S och Jörgen S för att ni är så sköna att ha i närheten och för att ni tar mig för den jag är.

Min Far, Obi, för att du är så generös och omtänksam. Du är toppen! Min syster, Jenifer, för att du står vid min sida i med och motgång. Söta Lina och Oscar, ni är ju för härliga. Karin J, tack för att du ställer upp som en extra-mor. Wickman familjen- för ert härliga välkomnade ute på vishan. Tommy, för din vänskap, kärlek och omtänksamhet och för att du är så skön att leva med.

Tack till alla som behandlat mig med stort överseende under avhandlingsarbetet, både privat och på jobbet.

41 References

REFERENCES

1. Meyer, K, and Palmer, J W. The polysaccharide of the vitreous humor. (1934) J. Biol. Chem. 107, 629-634

2. Fraser, J R E, Laurent, T C, and Laurent, U B G. Hyaluronan: its nature, distribution, functions and turnover. (1997) Journal of Internal Medicine 242, 27-33

3. Fessler, J H, and Fessler, L I. Electron microscope visualization of the polysaccharide hyaluronic acid. (1966) Proc Natl Acad Sci U S A 56, 141-147

4. Laurent, T C, and Fraser, J R E. Hyaluronan (1992) FASEB J. 6, 2397-2404

5. Scott, J E, and Heatley, F. Hyaluronan forms specific stable tertiary structures in aqueous solution: a 13C NMR study (1999) Proc Natl Acad Sci U S A 96, 4850-4855.

6. Laurent, T C. Structure of hyaluronic acid. (1970) Chemistry and molecular biology of the extracellular matrix. Balazs, E.A., Academic, London, 703-732

7. Lee, G M, Johnstone, B, Jacobson, K, and Caterson, B. The dynamic structure of the pericellular matrix on living cells (1993) J Cell Biol 123, 1899-1907.

8. Heldin, P, and Laurent, T C. (2000) in Saccharides in chemistry and biology: a comprehensive handbook (Ernst, B, Hart, G. and Sinay, P., ed), pp. 363-374, Wiley

9. Brecht, M, Mayer, U, Schlosser, E, and Prehm, P. Increased hyaluronate synthesis is required for fibroblast detachment and mitosis (1986) Biochem J 239, 445-450

10. Evanko, S P, Angello, J C, and Wight, T N. Formation of hyaluronan- and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells (1999) Arterioscler Thromb Vasc Biol 19, 1004-1013.

11. Evanko, S P, and Wight, T N. Intracellular localization of hyaluronan in proliferating cells (1999) J Histochem Cytochem 47, 1331-1342.

12. Greco, R M, Iocono, J A, and Ehrlich, H P. Hyaluronic acid stimulates human fibroblast proliferation within a collagen matrix (1998) J Cell Physiol 177, 465-473.

42 References

13. Chen, W Y J, Grant, M E, Schor, A M, and Schor, S L. Differences between adult and foetal fibroblasts in the regulation of hyaluronate synthesis: correlation with migratory activity (1989) J. Cell. Sci. 94, 577-584

14. Knudson, W. The role of CD44 as a cell surface hyaluronan receptor during tumor invasion of connective tissue (1998) Front Biosci 3, D604-615.

15. Li, Y, and Heldin, P. Hyaluronan production increases the malignant properties of mesothelioma cells (2001) Br J Cancer 85, 600-607.

16. Brinck, J, and Heldin, P. Expression of recombinant hyaluronan synthase (HAS) isoforms in CHO cells reduces cell migration and cell surface CD44 (1999) Exp Cell Res 252, 342- 351

17. Dube, B, Luke, H J, Aumailley, M, and Prehm, P. Hyaluronan reduces migration and proliferation in CHO cells (2001) Biochim Biophys Acta 1538, 283-289.

18. Hayen, W, Goebeler, M, Kumar, S, Riessen, R, and Nehls, V. Hyaluronan stimulates tumor cell migration by modulating the fibrin fiber architecture (1999) J Cell Sci 112, 2241- 2251.

19. Toole, B P. Developmental role of hyaluronate (1982) Connect Tissue Res 10, 93-100

20. Meyer, M F, and Kreil, G. Cells expressing the DG42 gene from early Xenopus embryos synthesize hyaluronan (1996) Proc Natl Acad Sci USA 93, 4543-4547

21. Camenisch, T D, Spicer, A P, Brehm-Gibson, T, Biesterfeldt, J, Augustine, M L, Calabro, A, Kubalak, S, Klewer, S E, and McDonald, J A. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme (2000) J Clin Invest 106, 349-360.

22. Laurent, T C, Laurent, U B G, and Fraser, J R E. Serum hyaluronan as a disease marker (1996) Ann. Med. 28, 241-253

23. Li, Y, Rahmanian, M, Widstrom, C, Lepperdinger, G, Frost, G I, and Heldin, P. Irradiation- induced expression of hyaluronan (HA) synthase 2 and hyaluronidase 2 genes in rat lung tissue accompanies active turnover of HA and induction of types I and III collagen gene expression (2000) Am J Respir Cell Mol Biol 23, 411-418.

43 References

24. Teder, P, and Heldin, P. Mechanism of impaired local hyaluronan turnover in bleomycin- induced lung injury in rat (1997) Am J Respir Cell Mol Biol 16, 376-385

25. Pure, E, and Cuff, C A. A crucial role for CD44 in inflammation (2001) Trends Mol Med 7, 213-221.

26. Mikecz, K, Brennan, F R, Kim, J H, and Glant, T T. Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis (1995) Nat Med 1, 558-563

27. West, D C, Shaw, D M, Lorenz, P, Adzick, N S, and Longaker, M T. Fibrotic healing of adult and late gestation fetal wounds correlates with increased hyaluronidase activity and removal of hyaluronan (1997) Int J Biochem Cell Biol 29, 201-210

28. Itano, N, and Kimata, K. Molecular cloning of human hyaluronan synthase (1996) Biochem Biophys Res Commun 222, 816-820

29. Shyjan, A M, Heldin, P, Butcher, E C, Yoshino, T, and Briskin, M J. Functional cloning of the cDNA for human hyaluronan synthase (1996) J Biol Chem 271, 23395-23399

30. Spicer, A P, Augustine, M L, and McDonald, J A. Molecular cloning and characterization of a putative mouse hyaluronan synthase (1996) J Biol Chem 271, 23400-23406

31. Spicer, A P, Olson, J S, and McDonald, J A. Molecular cloning and characterization of a cDNA encoding the third putative mammalian hyaluronan synthase (1997) J Biol Chem 272, 8957-8961

32. Jacobson, A, Brinck, J, Briskin, M J, Spicer, A P, and Heldin, P. Expression of human hyaluronan synthases in response to external stimuli (2000) Biochem J 348, 29-35.

33. Spicer, A P, Seldin, M F, Olsen, A S, Brown, N, Wells, D E, Doggett, N A, Itano, N, Kimata, K, Inazawa, J, and McDonald, J A. Chromosomal localization of the human and mouse hyaluronan synthase genes. (1997) Genomics 41, 493-497

34. Spicer, A P, and McDonald, J A. Characterization and molecular evolution of a vertebrate hyaluronan synthase gene family (1998) J Biol Chem 273, 1923-1932

44 References

35. DeAngelis, P L. Hyaluronan synthases: fascinating glycosyltransferases from vertebrates, becterial pathogens, and algal viruses (1999) cellular and molecular life sciences, 670- 682

36. Crater, D L, and van de Rijn, I. Hyaluronic acid synthesis operon (has) expression in group A streptococci (1995) J Biol Chem 270, 18452-18458

37. DeAngelis PL, Jing, W, Graves, M V, Burbank, D E, and Van Etten, J L. Hyaluronan synthase of chlorella virus PBCV-1 (1997) Science 278, 1800-1803.

38. DeAngelis, P L, and Weigel, P H. Immunochemical confirmation of the primary structure of Streptococcal hyaluronan synthase and synthesis of high molecular weight product by the recombinant enzyme (1994) Biochem 33, 9033-9039

39. DeAngelis, P, and Achyuthan, A. Yeast-derived recombinant DG42 protein of Xenopus can synthesize hyaluronan in vitro (1996) J Biol Chem 271, 23657-23660

40. Weigel, P, Hascall, V, and Tammi, M. Hyaluronan synthases (1997) J Biol Chem 272,, 13997-14000

41. Asplund, T, Brinck, J, Briskin, B J, Suzuki, M, and Heldin, P. Characterization of hyaluronan synthase from a human glioma cell line (1998) Biochimica et Biophysica Acta 1380, 377- 388

42. Itano, N, and Kimata, K. Expression, cloning and molecular characterization of HAS protein, a eukaryotic hyaluronan synthase (1996) J Biol Chem 271, 9875-9878

43. Prehm, P. Hyaluronate is synthesized at plasma membranes (1984) Biochem J 220, 597-600

44. Yoshida, M, Itano, N, Yamada, Y, and Kimata, K. In vitro synthesis of hyaluronan by a single protein derived from mouse HAS1 gene and characterization of amino acid residues essential for the activity (2000) J Biol Chem 275, 497-506.

45. Itano, N, Sawai, T, Yoshida, M, Lenas, P, Yamada, Y, Imagawa, M, Shinomura, T, Hamaguchi, M, Yoshida, Y, Ohnuki, Y, Miyauchi, S, Spicer, A P, McDonald, J A, and Kimata, K. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties (1999) J Biol Chem 274, 25085-25092

45 References

46. Stern, R, and Csoka, A B. Mammalian hyaluronidases (2000) www.glycoforum.gr.jp/science/hyaluronan/HA15/HA15E.html

47. Kreil, G. Hyaluronidases--a group of neglected enzymes (1995) Protein Sci 4, 1666-1669

48. Frost, G I, Csoka, T B, Wong, T, and Stern, R. Purification, cloning, and expression of human plasma hyaluronidase (1997) Biochem Biophys Res Commun 236, 10-15

49. Lepperdinger, G, Strobl, B, and Kreil, G. HYAL2, a human gene expressed in many cells, encodes a lysosomal hyaluronidase with a novel type of specificity (1998) J Biol Chem 273, 22466-22470

50. Strobl, B, Wechselberger, C, Beier, D R, and Lepperdinger, G. Structural organization and chromosomal localization of Hyal2, a gene encoding a lysosomal hyaluronidase (1998) Genomics 53, 214-219

51. Lepperdinger, G, Mullegger, J, and Kreil, G. Hyal2 - less active, but more versatile? (2001) Matrix Biol 20, 509-514.

52. Rai, S K, Duh, F M, Vigdorovich, V, Danilkovitch-Miagkova, A, Lerman, M I, and Miller, A D. Candidate tumor suppressor HYAL2 is a glycosylphosphatidylinositol (GPI)- anchored cell-surface receptor for jaagsiekte sheep retrovirus, the envelope protein of which mediates oncogenic transformation (2001) Proc Natl Acad Sci U S A 98, 4443- 4448.

53. Csoka, A B, Scherer, S W, and Stern, R. Expression analysis of six paralogous human hyaluronidase genes clustered on chromosomes 3p21 and 7q31 (1999) Genomics 60, 356-361.

54. Heldin, P, Laurent,T C, and Heldin, C-H. Effect of growth factors on hyaluronan synthesis in cultured human fibroblasts (1989) Biochem J 258, 919-922

55. Kaback, L A, and Smith, T J. Expression of hyaluronan synthase messenger ribonucleic acids and their induction by interleukin-1beta in human orbital fibroblasts: potential insight into the molecular pathogenesis of thyroid-associated ophthalmopathy (1999) J Clin Endocrinol Metab 84, 4079-4084

46 References

56. Heldin, C H, and Westermark, B. Mechanism of action and in vivo role of platelet-derived growth factor (1999) Physiol Rev 79, 1283-1316.

57. Miyazono, K, Ichijo, H, and Heldin, C H. Transforming growth factor-beta: latent forms, binding proteins and receptors (1993) Growth Factors 8, 11-22

58. Suzuki, M, Asplund, T, Yamashita, H, Heldin, C-H, and Heldin, P. Stimulation of hyaluronan biosynthesis by platelet-derived growth factor-BB and transforming growth factor-E1 involves activation of protein kinase C (1995) Biochem J 307, 817-821

59. Tirone E. D., A, C., Hascall, V.C., Siracusa, G., Salustri, A. Hyaluronan synthesis by mouse cumulus cells is regulated by interactions between follicle-stimulating hormone (or epidermal growth factor) and a soluble oocyte factor (or transforming growth factor beta1). (1997) J Biol Chem 272, 4787-4794

60. Sugiyama, Y, Shimada, A, Sayo, T, Sakai, S, and Inoue, S. Putative hyaluronan synthase mRNA are expressed in mouse skin and TGF-b upregulates their expresssion in cultured human skin cells (1998) J Invest Dermatol 110, 116-121

61. Pienimaki, J P, Rilla, K, Fulop, C, Sironen, R K, Karvinen, S, Pasonen, S, Lammi, M J, Tammi, R, Hascall, V C, and Tammi, M I. Epidermal growth factor activates hyaluronan synthase 2 in epidermal keratinocytes and increases pericellular and intracellular hyaluronan (2001) J Biol Chem 276, 20428-20435.

62. Evanko, S P, Johnson, P Y, Braun, K R, Underhill, C B, Dudhia, J, and Wight, T N. Platelet- derived growth factor stimulates the formation of versican- hyaluronan aggregates and pericellular matrix expansion in arterial smooth muscle cells (2001) Arch Biochem Biophys 394, 29-38.

63. Recklies, A D, White, C, Melching, L, and Roughley, P J. Differential regulation and expression of hyaluronan synthases in human articular chondrocytes, synovial cells and osteosarcoma cells (2001) Biochem J 354, 17-24.

64. Nishida, Y, Knudson, C B, Nietfeld, J J, Margulis, A, and Knudson, W. Antisense inhibition of hyaluronan synthase-2 in human articular chondrocytes inhibits proteoglycan retention and matrix assembly (1999) J Biol Chem 274, 21893-21899

47 References

65. Triggs-Raine, B, Salo, T J, Zhang, H, Wicklow, B A, and Natowicz, M R. Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX (1999) Proc Natl Acad Sci U S A 96, 6296-6300

66. Mio, K, Carrette, O, Maibach, H I, and Stern, R. Evidence that the serum inhibitor of hyaluronidase may be a member of the inter-alpha-inhibitor family (2000) J Biol Chem 275, 32413-32421.

67. Chang, N S. Transforming growth factor-beta protection of cancer cells against tumor necrosis factor cytotoxicity is counteracted by hyaluronidase (review) (1998) Int J Mol Med 2, 653-659

68. Banerji, S, Ni, J, Wang, S X, Clasper, S, Su, J, Tammi, R, Jones, M, and Jackson, D G. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan (1999) J Cell Biol 144, 789-801

69. Fieber, C, Plug, R, Sleeman, J, Dall, P, Ponta, H, and Hofmann, M. Characterisation of the murine gene encoding the intracellular hyaluronan receptor IHABP (RHAMM) (1999) Gene 226, 41-50

70. Zhang, S, Chang, M C, Zylka, D, Turley, S, Harrison, R, and Turley, E A. The hyaluronan receptor RHAMM regulates extracellular-regulated kinase (1998) J Biol Chem 273, 11342-11348

71. Politz, O, Gratchev, A, McCourt, P A, Schledzewski, K, Guillot, P, Johansson, S, Svineng, G, Franke, P, Kannicht, C, Kzhyshkowska, J, Longati, P, Velten, F W, and Goerdt, S. Stabilin-1 and -2 constitute a novel family of fasciclin-like hyaluronan receptor homologues (2002) Biochem J 362, 155-164.

72. Bono, P, Rubin, K, Higgins, J M, and Hynes, R O. Layilin, a novel integral membrane protein, is a hyaluronan receptor (2001) Mol Biol Cell 12, 891-900.

73. Knudson, C B, and Knudson, W. Hyaluronan-binding proteins in development, tissue homeostasis, and disease (1993) FASEB J. 7, 1233-1241

74. Knudson, W, Biswas, C, Li, X-Q, Nemec, R E, and Toole, B P. (1989) in The biology of hyaluronan (Evered, D, and Whelan, J, eds) Vol. 143, pp. 150-169, Wiley, Chichester

48 References

75. Pirinen, R T, Tammi, R H, Tammi, M I, Paakko, P K, Parkkinen, J J, Agren, U M, Johansson, R T, Viren, M M, Tormanen, U, Soini, Y M, and Kosma, V M. Expression of hyaluronan in normal and dysplastic bronchial epithelium and in squamous cell carcinoma of the lung (1998) Int J Cancer 79, 251-255.

76. Kosaki, R, Watanabe, K, and Yamaguchi, Y. Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity (1999) Cancer Res 59, 1141-1145

77. Dobra, K, Andang, M, Syrokou, A, Karamanos, N K, and Hjerpe, A. Differentiation of mesothelioma cells is influenced by the expression of proteoglycans (2000) Exp Cell Res 258, 12-22.

78. Simpson, M A, Wilson, C M, Furcht, L T, Spicer, A P, Oegema, T R, Jr., and McCarthy, J B. Manipulation of hyaluronan synthase expression in prostate adenocarcinoma cells alters pericellular matrix retention and adhesion to bone marrow endothelial cells (2002) J Biol Chem 14, 14

79. Liu, N, Gao, F, Han, Z, Xu, X, Underhill, C B, and Zhang, L. Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells (2001) Cancer Res 61, 5207-5214.

80. Ropponen, K, Tammi, M, Parkkinen, J, Eskelinen, M, Tammi, R, Lipponen, P, Agren, U, Alhava, E, and Kosma, V M. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer (1998) Cancer Res 58, 342-347.

81. Bohm, J, Niskanen, L, Tammi, R, Tammi, M, Eskelinen, M, Pirinen, R, Hollmen, S, Alhava, E, and Kosma, V M. Hyaluronan expression in differentiated thyroid carcinoma (2002) J Pathol 196, 180-185.

82. Csoka, T B, Frost, G I, Heng, H H, Scherer, S W, Mohapatra, G, and Stern, R. The hyaluronidase gene HYAL1 maps to chromosome 3p21.2-p21.3 in human and 9F1-F2 in mouse, a conserved candidate tumor suppressor (1998) Genomics 48, 63-70

83. Frost, G I, Mohapatra, G, Wong, T M, Csoka, A B, Gray, J W, and Stern, R. HYAL1LUCA- 1, a candidate tumor suppressor gene on chromosome 3p21.3, is inactivated in head and neck squamous cell carcinomas by aberrant splicing of pre-mRNA (2000) Oncogene 19, 870-877.

49 References

84. De Maeyer-Guignard, J, Lauret, E, Eusebe, L, and De Maeyer, E. Accelerated tumor development in interferon-treated B6.C-Hyal-1 a mice (1993) Proc Natl Acad Sci U S A 90, 5708-5712.

85. Lin, G, and Stern, R. Plasma hyaluronidase (Hyal-1) promotes tumor cell cycling (2001) Cancer Lett 163, 95-101.

86. Novak, U, Stylli, S S, Kaye, A H, and Lepperdinger, G. Hyaluronidase-2 overexpression accelerates intracerebral but not subcutaneous tumor formation of murine astrocytoma cells (1999) Cancer Res 59, 6246-6250.

87. Shweiki, D, Itin, A, Soffer, D, and Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis (1992) Nature 359, 843-845.

88. West, D C, Hampson, I N, Arnold, F, and Kumar, S. Angiogenesis induced by degradation products of hyaluronic acid (1985) Science 228, 1324-1326

89. Liu, D, Pearlman, E, Diaconu, E, Guo, K, Mori, H, Haqqi, T, Markowitz, S, Willson, J, and Sy, M S. Expression of hyaluronidase by tumor cells induces angiogenesis in vivo (1996) Proc Natl Acad Sci U S A 93, 7832-7837.

90. Jacobson, A, Rahmanian, M., Rubin, K., Heldin, P. Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors (2002) Submitted Int J Cancer

91. Rahmanian, M, and Heldin, P. Testicular hyaluronidase induces tubular structures of endothelial cells grown in three-dimensional colagen gel through a CD44-mediated mechanism (2002) Int J Cancer 97, 601-607.

92. Cao, H, Pratt, N, Mattison, J, Zhao, Y, and Chang, N S. Characterization of an apoptosis inhibitory domain at the C-termini of FE65-like protein (2000) Biochem Biophys Res Commun 276, 843-850.

93. Rubin, E, and Farber, J L. (1988) in Pathology, second edition (Winters, R, Schott, J., Muccie, M. R., ed), pp. 690-695, J.B. Lippincott company, Philadelphia 94. Willett, W C. Diet and cancer (2000) Oncologist 5, 393-404

50 References

95. Strong, S. Hyaluronan and colon smooth muscle cells (1999) www.glycoforum.gr.jp/science/hyaluronan/HA15/HA15E.html

96. Mulder, J W, Kruyt, P M, Sewnath, M, Oosting, J, Seldenrijk, C A, Weidema, W F, Offerhaus, G J, and Pals, S T. Colorectal cancer prognosis and expression of exon-v6- containing CD44 proteins (1994) Lancet 344, 1470-1472.

97. Takahashi, K, Stamenkovic, I, Cutler, M, Saya, H, and Tanabe, K K. CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas (1995) Oncogene 11, 2223-2232

98. Wang, C, Tammi, M, Guo, H, and Tammi, R. Hyaluronan distribution in the normal epithelium of esophagus, stomach, and colon and their cancers (1996) Am J Pathol 148, 1861-1869.

99. Bi, J, and Lu, B. Advances in the diagnosis and management of thyroid neoplasms (2000) Curr Opin Oncol 12, 54-59.

100. Dahlman, T, Lammerts, E, Wik, M, Bergstrom, D, Grimelius, L, Westermark, K, Rubin, K, and Heldin, N E. Fibrosis in undifferentiated (anaplastic) thyroid carcinomas: evidence for a dual action of tumour cells in collagen type I synthesis (2000) J Pathol 191, 376- 386.

101. Martin, M, Ahlen, K, Dimanche-Boitrel, M T, Mendrick, D L, Turner, D C, Rubin, K, and Martin, F. Colon-cancer cell variants producing regressive tumors in syngeneic rats, unlike variants yielding progressive tumors, attach to interstitial collagens through integrin alpha2beta1 (1996) Int J Cancer 65, 796-804.

102. Gundersen, H J, Bendtsen, T F, Korbo, L, Marcussen, N, Moller, A, Nielsen, K, Nyengaard, J R, Pakkenberg, B, Sorensen, F B, Vesterby, A, and et al. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis (1988) Apmis 96, 379-394.

103. Asplund, T, Versnel, M A, Laurent, T C, and Heldin, P. Human mesothelioma cells produce factors that stimulate the production of hyaluronan by mesothelial cells and fibroblasts (1993) Cancer Res 53, 388-392

51 References

104. Wiig, H, Tveit, E, Hultborn, R, Reed, R K, and Weiss, L. Interstitial fluid pressure in DMBA-induced rat mammary tumours (1982) Scand J Clin Lab Invest 42, 159-164.

105. Lammerts, E, Roswall, P, Sundberg, C, Gotwals, P J, Koteliansky, V E, Reed, R K, Heldin, N E, and Rubin, K. Interference with TGF-b1 and -b3 in tumor stroma loweres interstitual fluid pressure independently of growth in experimental carcinoma (2002) Int J Cancer, In press

106. West, D C, and Kumar, S. (1989) The biology of hyaluronan (Evered, D, and Whelan, J, eds) Vol. 143, pp. 187-201, Wiley, Chichester

107. Qi, Z, Atsuchi, N, Ooshima, A, Takeshita, A, and Ueno, H. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat (1999) Proc Natl Acad Sci U S A 96, 2345-2349.

108. Brekken, C, Bruland, O S, and de Lange Davies, C. Interstitial fluid pressure in human osteosarcoma xenografts: significance of implantation site and the response to intratumoral injection of hyaluronidase (2000) Anticancer Res 20, 3503-3512.

52